This interview is with Gene Regulation and Systems Biology editorial board member Dr Frederick Domann. Gene Regulation and Systems Biology is an open access journal published by Libertas Academica.
Editor in Chief Dr James Willey has recently issued a call for papers.
What is the primary focus of your work and main areas of expertise?
Our laboratory is primarily interested in the effects of redox metabolism on epigenetic control of chromatin structure and gene expression in cancer. Our main areas of expertise include free radical biology, mitochondrial metabolism, DNA methylation, and histone modifications.
What are the most exciting and cutting-edge developments in your area?
The recent discovery of the lysine demethylase (KDM) family of enzymes, and the realization that these are 2-oxoglutarate dependent dioxygenases, has provided a direct conceptual link between the redox biochemistry of central metabolism and establishment and maintenance of epigenomic landscapes. Equally or even more exciting is the very recent discovery of 5-hydroxy-methylcytosine as the "6th base" within DNA, and that the enzyme that catalyzes its formation, TET1, is apparently also a 2-oxoglutarate dependent dioxygenase! The significance of 5-OH-methylcytosine in genomic DNA is unknown, but we speculate that it may be an intermediate in an active process of oxidative cytosine demethylation. These findings will have enormous impacts in our long-term understanding of epigenetic mechanisms that govern development and cancer.
Who are your main formal and informal collaborators and/or networks? Please describe your work with them.
We have had a long standing collaboration with the Futscher lab at the University of Arizona to examine epigenetic control of gene expression in cancer and in normal human cells. Together, we were the first to demonstrate unequivocally a role for cytosine methylation in normal cell type specific expression of a gene known as SERPINB5 (Nature Genetics 31, 175-9, 2002). We have recently begun a collaboration with Jeannie Lee to examine the role of redox metabolism on epigenetic determinants of X-chromosome inactivation state during the establishment and maintenance of human induce pluripotential stem cells (hiPS).
How did you come to be working in your research area?
Through a long-standing interest in redox biochemistry associated with oxygen toxicity and radiation injury stemming from my graduate studies. Then a blossoming interest in epigenetic control mechanisms, beginning with DNA methylation, fueled a deeper interest in identifying conceptual and practical links between epigenetic control mechanisms and redox biology.
What do you think about the development of open access publishing? Have you published in an open access journal? What motivated you to do so?
I believe that open access publishing is likely to be the wave of the future. I have published in open access journals as they are freely available to individuals even without a subscription. The newest literature is much more broadly and instantly available. Open access has certainly provided an alternative avenue for publication for important findings that may not have had a chance at more traditional journals.
Further Information
Graduate Program
Research Interests
Tuesday, July 20, 2010
Thursday, July 15, 2010
Author interview with Dr Akimune Fukushima
Dr Fukushima is the author of Assessment of Fetal Autonomic Nervous System Activity by Fetal Magnetocardiography which was recently published in Clinical Medicine Insights: Cardiology.
The Editor in Chief of Clinical Medicine Insights: Cardiology recently issued a call for papers.
Dr Fukushima is a member of our favorite authors program. Under the program authors are eligible to receive: prioritized peer review, prioritised author PDF, and an article processing fee discount. All former authors are eligible to join the favorite authors program.
What is the primary focus of your research?
Evaluating the fetal autonomic nervous system developement with non-invasive technology such as magnetocardiography (MCG).
What are the most exciting developments arising from current research in your area?
Fetal magnetocardiography(FMCG) was the most exciting development.
Who are your main collaborators? Please describe your work with them.
Dr. Kenji Nakai who is a cardiologist. He did most of the FMCG arrangements.
How did you come to be working in your research area?
My main work is the clinical Obstetrics. Prenatal diagnosis and assesment of the fetus are the most important part of my job. I am also interseted in non-invasive technology. From both standpoint of veiw, I started to join this research area.
What do you think about the development of open access publishing? What motivated you to do so?
I felt very borderless, both time and distance. I was very impressed with the quick response from the editor.
What articles and/or books have you published recently?
“Prenatal Diagnosis of Recurrent Ventricular Tachycardia using 64-channel Magnetocardiography” Heart and Vessels 2009 in press.
The Editor in Chief of Clinical Medicine Insights: Cardiology recently issued a call for papers.
Dr Fukushima is a member of our favorite authors program. Under the program authors are eligible to receive: prioritized peer review, prioritised author PDF, and an article processing fee discount. All former authors are eligible to join the favorite authors program.
What is the primary focus of your research?
Evaluating the fetal autonomic nervous system developement with non-invasive technology such as magnetocardiography (MCG).
What are the most exciting developments arising from current research in your area?
Fetal magnetocardiography(FMCG) was the most exciting development.
Who are your main collaborators? Please describe your work with them.
Dr. Kenji Nakai who is a cardiologist. He did most of the FMCG arrangements.
How did you come to be working in your research area?
My main work is the clinical Obstetrics. Prenatal diagnosis and assesment of the fetus are the most important part of my job. I am also interseted in non-invasive technology. From both standpoint of veiw, I started to join this research area.
What do you think about the development of open access publishing? What motivated you to do so?
I felt very borderless, both time and distance. I was very impressed with the quick response from the editor.
What articles and/or books have you published recently?
“Prenatal Diagnosis of Recurrent Ventricular Tachycardia using 64-channel Magnetocardiography” Heart and Vessels 2009 in press.
Author interview with Dr Sanjoy K. Bhattacharya
Dr Bhattacharya is the author of Prospects for Proteomics Directed Genomic and Genetic Analyses in Disease Discoveries which was recently published in Proteomics Insights.
The Editor in Chief of Proteomics Insights recently issued a call for papers.
Dr Bhattacharya is a member of our favorite authors program. Under the program authors are eligible to receive: prioritized peer review, prioritised author PDF, and an article processing fee discount. All former authors are eligible to join the favorite authors program.
What is the primary focus of your research?
Our primary focus is on Glaucoma. Glaucomas are irreversible blinding diseases that are termed primary when no injury or illness can be ascribed to them or secondary when a initiating cause can be attributed for onset. Depending on the angle between iris and cornea they are termed as open or angle closure glaucoma. Aqueous is a clear liquid that is produced in the ciliary epithelium which traverses to cornea and serves the function of providing nutrients and taking away excretory material from cornea. In glaucoma the outflow of aqueous humor is often impaired experiencing more resistance to flow at a region termed trabecular meshwork. We apply the technique of proteomics to analyze anterior and posterior eye tissue. In the anterior chamber our analyses revealed presence of a protein termed cochlin in the trabecular meshwork region of the anterior chamber. In the posterior chamber, in the optic nerve, the tissue that is affected in glaucoma, we have identified peptidyl arginine deiminase 2 (PAD2) by proteomic mass spectrometry.
What are the most exciting developments arising from current research in your area?
An imbalance between aqueous production and outflow results in increased intraocular pressure (IOP), a major risk factor for glaucoma. Subsequent follow up after proteomic identification in our laboratory and others now has revealed the possible association of cochlin with increase in IOP. This is an exciting development and we are embarking on mechanistic research along these lines.
In the optic nerve we have identified PAD2 by proteomic analysis. PAD2 and its posttranslation modification (deimination) are elevated in glaucoma as well as another neurodegenerative disease: multiple sclerosis. We have discovered some interesting aspect of cell specific differences in alteration in both PAD2 and deimination in neurodegenerative tissues.
Who are your main collaborators? Please describe your work with them.
My main collaborator in Glaucoma research for the anterior chamber part, is Professor Paul L. Kaufman, Professor and Chair of the Department of Ophthalmology and Visual Sciences at University of Wisconsin. My other collaborators in this research are my colleagues Dr. Richard K. Lee and Anna K. Junk at University of Miami. Drs. Lee and Junk are physician scientists and my research is immensely benefitted from collaboration with them. My former postdoctoral fellows Dr. Renata Picciani, a clinician scientist, now at Temple University Philadelphia, also continues to collaborate with me on this research. My former graduate student Dr. Bharathi Govindarajan, now a postdoctoral fellow at Schepens Eye Institute at Harvard Medical School also continues to discuss interesting science and shares her thoughts occasionally pertaining to trabecular meshwork.
My collaborators for the optic nerve and PAD2 are Professor Hidenari Takahara from University of Ibaraki, Japan and Professor Mario A. Moscarello and Dr. Fabrizio Mastronardi from University of Toronto. With Dr. Takahara and in collaboration with Dr. James Wilson of Department of Chemistry, University of Miami and Drs. Terry Lee and George Kapsalis, we are trying to develop a new method to detect product of PAD2 or deiminated arginine residues. With Drs. Moscarello and Mastronardi, we are trying to evaluate status of deimination in different retinal cells of a transgenic mice of multiple sclerosis termed ND4 mice. Graduate students, Di Ding and Mabel Algeciras are involved in this project. A significant collaborator on detecting functional ocular status with respect to deimination is Dr. Vittorio Porciatti. Dr. Porciatti at our institute is an world expert on pattern electroretinogram (PERG). We apply PERG for determining visual outcome in ND4 mice (PLP transgenic ND4) in collaboration with Dr. Porciatti.
Another area where we apply proteomic analysis is corneal diseases and corneal droplet keratopathy in collaboration with Drs. Horacio M. Serra and Julio Urrets-Zavalia from Cordoba, Argentina.
How did you come to be working in your research area?
I graduated as a biochemical engineer and did not free-lance work as biochemical engineer with great renumeration. However, I was not intellectually satisfied. I entered into doctoral research despite a great remunerative career, partly due to the intellectual frustation as a biochemical engineer whether things are largely routine after some time. I worked on DNA methylation during my doctoral thesis and in my first postdoctoral stint. I went to learn briefly the structural biology and X-ray crystallography of proteins. Due to irrational nature of crystallization process I used to subject the malformed crystalls proteomic mass spectrometric analysis.
It is during this time that I came to the Cole Eye Institute at Cleveland to learn proteomics to analyze my crystalls. However, after attending a few seminars my interest in the ophthalmology and proteomics intensified and I transferred to Cole Eye Institute from structral biology program. I noticed that everyone at Cole Eye Institute, ophthalmic research was engaged in basic research in retina. Despite Glaucoma being a major blinding disease, no basic research was carried out at Cole Eye Institute. I also recognized the importance and availability of vast volume of surgical tissue (trabecular meshwork) that was wasted. These details prompted me to take an independent initiative in Glaucoma research and I must admit it had been a very rewarding initiative. The importance of my research was almost immediately realized and within two years of embarking into this research I was offered an independent faculty position from Bascom Palmer Eye Institute at University of Miami. Bascom Palmer Eye Institute has been ranked number one according to US News and World report consecutively for last five years. The proteins that I identified in my initial analysis are showing promising results on further analysis and more appears yet to come.
What do you think about the development of open access publishing? What motivated you to do so?
The open access publishing makes everything instantly available. It is not irritating that one has to pay or go to a library to access the article. I thinkit is a great model.
What articles and/or books have you published recently?
I publish about 12 articles every year. In 2010, there will be two prominent articles about systems biology that will be published are in (a) Wiley International Reviews in Systems Biology and in (b) Systems and Sythetic Biology.
A few recently published article available in PUBMED are:
COCH Transgene Expression by Adenovirus in Cultured Human Trabecular Meshwork Cells and Its Effect on Outflow Facility in Monkey Organ Cultured Anterior Segments.Lee ES, Gabelt BT, Faralli JA, Peters DM, Brandt CR, Kaufman PL, Bhattacharya SK.Invest Ophthalmol Vis Sci. 2009 Nov 20. [Epub ahead of print] PMID: 19933177 [PubMed - as supplied by publisher]
Proteomics characterization of cell membrane blebs in human retinal pigment epithelium cells.Alcazar O, Hawkridge AM, Collier TS, Cousins SW, Bhattacharya SK, Muddiman DC, Marin-Castano ME. Mol Cell Proteomics. 2009 Oct;8(10):2201-11. Epub 2009 Jun 29.PMID: 19567368 [PubMed - in process]
Retinal deimination in aging and disease.Bhattacharya SK.
IUBMB Life. 2009 May;61(5):504-9.Aug;61(8):864. PMID: 19391158 [PubMed - indexed for MEDLINE]
I have also published two important review articles in "Proteomics Insights" and in "Biochemistry Insights" respectively in 2009.
Additional Information
Faculty Website
The Editor in Chief of Proteomics Insights recently issued a call for papers.
Dr Bhattacharya is a member of our favorite authors program. Under the program authors are eligible to receive: prioritized peer review, prioritised author PDF, and an article processing fee discount. All former authors are eligible to join the favorite authors program.
What is the primary focus of your research?
Our primary focus is on Glaucoma. Glaucomas are irreversible blinding diseases that are termed primary when no injury or illness can be ascribed to them or secondary when a initiating cause can be attributed for onset. Depending on the angle between iris and cornea they are termed as open or angle closure glaucoma. Aqueous is a clear liquid that is produced in the ciliary epithelium which traverses to cornea and serves the function of providing nutrients and taking away excretory material from cornea. In glaucoma the outflow of aqueous humor is often impaired experiencing more resistance to flow at a region termed trabecular meshwork. We apply the technique of proteomics to analyze anterior and posterior eye tissue. In the anterior chamber our analyses revealed presence of a protein termed cochlin in the trabecular meshwork region of the anterior chamber. In the posterior chamber, in the optic nerve, the tissue that is affected in glaucoma, we have identified peptidyl arginine deiminase 2 (PAD2) by proteomic mass spectrometry.
What are the most exciting developments arising from current research in your area?
An imbalance between aqueous production and outflow results in increased intraocular pressure (IOP), a major risk factor for glaucoma. Subsequent follow up after proteomic identification in our laboratory and others now has revealed the possible association of cochlin with increase in IOP. This is an exciting development and we are embarking on mechanistic research along these lines.
In the optic nerve we have identified PAD2 by proteomic analysis. PAD2 and its posttranslation modification (deimination) are elevated in glaucoma as well as another neurodegenerative disease: multiple sclerosis. We have discovered some interesting aspect of cell specific differences in alteration in both PAD2 and deimination in neurodegenerative tissues.
Who are your main collaborators? Please describe your work with them.
My main collaborator in Glaucoma research for the anterior chamber part, is Professor Paul L. Kaufman, Professor and Chair of the Department of Ophthalmology and Visual Sciences at University of Wisconsin. My other collaborators in this research are my colleagues Dr. Richard K. Lee and Anna K. Junk at University of Miami. Drs. Lee and Junk are physician scientists and my research is immensely benefitted from collaboration with them. My former postdoctoral fellows Dr. Renata Picciani, a clinician scientist, now at Temple University Philadelphia, also continues to collaborate with me on this research. My former graduate student Dr. Bharathi Govindarajan, now a postdoctoral fellow at Schepens Eye Institute at Harvard Medical School also continues to discuss interesting science and shares her thoughts occasionally pertaining to trabecular meshwork.
My collaborators for the optic nerve and PAD2 are Professor Hidenari Takahara from University of Ibaraki, Japan and Professor Mario A. Moscarello and Dr. Fabrizio Mastronardi from University of Toronto. With Dr. Takahara and in collaboration with Dr. James Wilson of Department of Chemistry, University of Miami and Drs. Terry Lee and George Kapsalis, we are trying to develop a new method to detect product of PAD2 or deiminated arginine residues. With Drs. Moscarello and Mastronardi, we are trying to evaluate status of deimination in different retinal cells of a transgenic mice of multiple sclerosis termed ND4 mice. Graduate students, Di Ding and Mabel Algeciras are involved in this project. A significant collaborator on detecting functional ocular status with respect to deimination is Dr. Vittorio Porciatti. Dr. Porciatti at our institute is an world expert on pattern electroretinogram (PERG). We apply PERG for determining visual outcome in ND4 mice (PLP transgenic ND4) in collaboration with Dr. Porciatti.
Another area where we apply proteomic analysis is corneal diseases and corneal droplet keratopathy in collaboration with Drs. Horacio M. Serra and Julio Urrets-Zavalia from Cordoba, Argentina.
How did you come to be working in your research area?
I graduated as a biochemical engineer and did not free-lance work as biochemical engineer with great renumeration. However, I was not intellectually satisfied. I entered into doctoral research despite a great remunerative career, partly due to the intellectual frustation as a biochemical engineer whether things are largely routine after some time. I worked on DNA methylation during my doctoral thesis and in my first postdoctoral stint. I went to learn briefly the structural biology and X-ray crystallography of proteins. Due to irrational nature of crystallization process I used to subject the malformed crystalls proteomic mass spectrometric analysis.
It is during this time that I came to the Cole Eye Institute at Cleveland to learn proteomics to analyze my crystalls. However, after attending a few seminars my interest in the ophthalmology and proteomics intensified and I transferred to Cole Eye Institute from structral biology program. I noticed that everyone at Cole Eye Institute, ophthalmic research was engaged in basic research in retina. Despite Glaucoma being a major blinding disease, no basic research was carried out at Cole Eye Institute. I also recognized the importance and availability of vast volume of surgical tissue (trabecular meshwork) that was wasted. These details prompted me to take an independent initiative in Glaucoma research and I must admit it had been a very rewarding initiative. The importance of my research was almost immediately realized and within two years of embarking into this research I was offered an independent faculty position from Bascom Palmer Eye Institute at University of Miami. Bascom Palmer Eye Institute has been ranked number one according to US News and World report consecutively for last five years. The proteins that I identified in my initial analysis are showing promising results on further analysis and more appears yet to come.
What do you think about the development of open access publishing? What motivated you to do so?
The open access publishing makes everything instantly available. It is not irritating that one has to pay or go to a library to access the article. I thinkit is a great model.
What articles and/or books have you published recently?
I publish about 12 articles every year. In 2010, there will be two prominent articles about systems biology that will be published are in (a) Wiley International Reviews in Systems Biology and in (b) Systems and Sythetic Biology.
A few recently published article available in PUBMED are:
COCH Transgene Expression by Adenovirus in Cultured Human Trabecular Meshwork Cells and Its Effect on Outflow Facility in Monkey Organ Cultured Anterior Segments.Lee ES, Gabelt BT, Faralli JA, Peters DM, Brandt CR, Kaufman PL, Bhattacharya SK.Invest Ophthalmol Vis Sci. 2009 Nov 20. [Epub ahead of print] PMID: 19933177 [PubMed - as supplied by publisher]
Proteomics characterization of cell membrane blebs in human retinal pigment epithelium cells.Alcazar O, Hawkridge AM, Collier TS, Cousins SW, Bhattacharya SK, Muddiman DC, Marin-Castano ME. Mol Cell Proteomics. 2009 Oct;8(10):2201-11. Epub 2009 Jun 29.PMID: 19567368 [PubMed - in process]
Retinal deimination in aging and disease.Bhattacharya SK.
IUBMB Life. 2009 May;61(5):504-9.Aug;61(8):864. PMID: 19391158 [PubMed - indexed for MEDLINE]
I have also published two important review articles in "Proteomics Insights" and in "Biochemistry Insights" respectively in 2009.
Additional Information
Faculty Website
Author interview with Dr Leonid Omelyanchuk
Dr Omelyanchuk is the author of Evolution and Origin of HRS, a Protein Interacting with Merlin, the Neurofibromatosis 2 Gene Product which was recently published in Gene Regulation and Systems Biology.
The Editor in Chief of Gene Regulation and Systems Biology recently issued a call for papers.
Dr Omelyanchuk is a member of our favorite authors program. Under the program authors are eligible to receive: prioritized peer review, prioritised author PDF, and an article processing fee discount. All former authors are eligible to join the favorite authors program.
Please describe your experience with Libertas Academica:
Science is an interesting thing. I feel that LA consider novelity and originality of research as very essential criterions.
What is the primary focus of your research?
Cellular function of Tumor-suppresor proteins.
What are the most exciting developments arising from current research in your area?
We see that in addition to the proliferation regulation in somatic tissue, those proteins also have an additional functions in a germ-line.
Who are your main collaborators? Please describe your work with them.
We had a joint Merlin tumor-suppressor project W81XWH-04-1-0509 with Dr. Long-Sheng Chang supported by US Army Medical Research Foundation. My group in Novosibirsk was working with drosophila Merlin, while Long-Sheng laboratory with mouse and human NF2.
In the past we were also working with S.Nokkala and J. Mattila from Turku University (Finland).
How did you come to be working in your research area?
I had made PhD (1987) in Molecular Evolution. In particular I had found that antigenic determinants of influenza virus have more non-synonimous that synonimous amino acid changes. Now days this effect is called as "positive selection". After that I started to work in radiation genetics on drosophila object. During this time Russian Science start to transit to grant system and I could not find a room for radiobiological study and moved to the cell-cycle. Ater a few years in the Cell-Cycle field it become evident (From A.Garcia-Bellido, P. Bryant and B.Edgar papers) that the most interesting task is how Cell-cycle is regulated in tissues.
What do you think about the development of open access publishing? What motivated you to do so?
Advanced and perspective.
What articles and/or books have you published recently?
A GFP trap study uncovers the functions of Gilgamesh protein kinase in Drosophila melanogaster spermatogenesis. Nerusheva OO, Dorogova NV, Gubanova NV, Yudina OS, Omelyanchuk LV. Cell Biol. Int. 2009, 33(5):586-93.
Leonid V. Omelyanchuk, Julya A. Pertseva and John M. Saul Evolutionary Origin of the Tumor Suppressor Hyperplastic Discs Protein. In Silico Biology 9 (2009) 1–5.
Lemos CL, Sampaio P, Maiato H, Costa M, Omel'yanchuk LV, Liberal V, Sunkel CE.
Mast, a conserved microtubule-associated protein required for bipolar mitotic spindle organization EMBO JOURNAL 2000,19 (14): 3668-3682.
Mattila J, Omelyanchuk L, Kyttala S, Turunen H, Nokkala S. Role of Jun N-terminal Kinase (JNK) signaling in the wound healing and regeneration of a Drosophila melanogaster wing imaginal disc Int J Dev Biol. 2005;49(4):391-9.
Golovnina K, Blinov A, Akhmametyeva EM, Omelyanchuk LV, Chang LS. Evolution and origin of merlin, the product of the Neurofibromatosis type 2 (NF2) tumor-suppressor gene BMC Evol Biol. 2005;5:69.
Dorogova NV, Akhmametyeva EM, Kopyl SA, Gubanova NV, Yudina OS, Omelyanchuk LV, Chang LS. The role of Drosophila Merlin in spermatogenesis. BMC Cell Biol. 2008;9(1):1.
The Editor in Chief of Gene Regulation and Systems Biology recently issued a call for papers.
Dr Omelyanchuk is a member of our favorite authors program. Under the program authors are eligible to receive: prioritized peer review, prioritised author PDF, and an article processing fee discount. All former authors are eligible to join the favorite authors program.
Please describe your experience with Libertas Academica:
Science is an interesting thing. I feel that LA consider novelity and originality of research as very essential criterions.
What is the primary focus of your research?
Cellular function of Tumor-suppresor proteins.
What are the most exciting developments arising from current research in your area?
We see that in addition to the proliferation regulation in somatic tissue, those proteins also have an additional functions in a germ-line.
Who are your main collaborators? Please describe your work with them.
We had a joint Merlin tumor-suppressor project W81XWH-04-1-0509 with Dr. Long-Sheng Chang supported by US Army Medical Research Foundation. My group in Novosibirsk was working with drosophila Merlin, while Long-Sheng laboratory with mouse and human NF2.
In the past we were also working with S.Nokkala and J. Mattila from Turku University (Finland).
How did you come to be working in your research area?
I had made PhD (1987) in Molecular Evolution. In particular I had found that antigenic determinants of influenza virus have more non-synonimous that synonimous amino acid changes. Now days this effect is called as "positive selection". After that I started to work in radiation genetics on drosophila object. During this time Russian Science start to transit to grant system and I could not find a room for radiobiological study and moved to the cell-cycle. Ater a few years in the Cell-Cycle field it become evident (From A.Garcia-Bellido, P. Bryant and B.Edgar papers) that the most interesting task is how Cell-cycle is regulated in tissues.
What do you think about the development of open access publishing? What motivated you to do so?
Advanced and perspective.
What articles and/or books have you published recently?
A GFP trap study uncovers the functions of Gilgamesh protein kinase in Drosophila melanogaster spermatogenesis. Nerusheva OO, Dorogova NV, Gubanova NV, Yudina OS, Omelyanchuk LV. Cell Biol. Int. 2009, 33(5):586-93.
Leonid V. Omelyanchuk, Julya A. Pertseva and John M. Saul Evolutionary Origin of the Tumor Suppressor Hyperplastic Discs Protein. In Silico Biology 9 (2009) 1–5.
Lemos CL, Sampaio P, Maiato H, Costa M, Omel'yanchuk LV, Liberal V, Sunkel CE.
Mast, a conserved microtubule-associated protein required for bipolar mitotic spindle organization EMBO JOURNAL 2000,19 (14): 3668-3682.
Mattila J, Omelyanchuk L, Kyttala S, Turunen H, Nokkala S. Role of Jun N-terminal Kinase (JNK) signaling in the wound healing and regeneration of a Drosophila melanogaster wing imaginal disc Int J Dev Biol. 2005;49(4):391-9.
Golovnina K, Blinov A, Akhmametyeva EM, Omelyanchuk LV, Chang LS. Evolution and origin of merlin, the product of the Neurofibromatosis type 2 (NF2) tumor-suppressor gene BMC Evol Biol. 2005;5:69.
Dorogova NV, Akhmametyeva EM, Kopyl SA, Gubanova NV, Yudina OS, Omelyanchuk LV, Chang LS. The role of Drosophila Merlin in spermatogenesis. BMC Cell Biol. 2008;9(1):1.
Wednesday, July 14, 2010
Author interview with Dr Esther Uña Cidón
Dr Uña Cidón is the author of A Commentary on “Risk Factors for Renal Cell Cancer in a Japanese Population” and Gastric Adenocarcinoma: Is Computed Tomography (CT) Useful in Preoperative Staging? which were recently published in Clinical Medicine Insights: Oncology.
The Editor in Chief of Clinical Medicine Insights: Oncology recently issued a call for papers.
Dr Uña Cidón is a member of our favorite authors program. Under the program authors are eligible to receive: prioritized peer review, prioritised author PDF, and an article processing fee discount. All former authors are eligible to join the favorite authors program.
Please describe your experience with Libertas Academica:
I would like to say that my experience with Libertas Academica has been excellent. The steps for submitting a manuscript are easy. The review process has been fast and reviewers comments have been kind and very qualified. The communication with the staff is fluent and friendly. I like the regular updates of the progress of my submitted manuscript. I appreciate these advantages.
What is the primary focus of your research?
Now and in the past my clinical research has focused primarily on gastrointestinal tumors, mainly colorectal and gastric neoplasms. I have been working on several projects related with new clinical and pathological prognostic/predictive factors, tumoral markers and its clinical utility in different clinical scenarios and biomarkers. My work has also explored the relationship between costs and effectiveness of various strategies for monitoring colon cancer.
What are the most exciting developments arising from current research in your area?
The discovery of new biomarkers in gastrointestinal tumors.
Who are your main collaborators? Please describe your work with them.
I had the good fortune of working with experts from many different fields, including pathologists, radiotherapists, surgeons, biochemical colleagues, gastroenterologists, radiologists, pharmacists... They all have been very motivated by this research. Currently the teams are multidisciplinary because this is the only way to achieve the best care for the patients and the most competent research.
How did you come to be working in your research area?
I am a young Medical Oncologist with a great interest in improving quality of care in gastrointestinal tumors. I realize that as a first step to achieve the best quality of care in current clinical practice is the motivation of all specialists involved in cancer care and close collaboration within multidisciplinary teams. But I am also aware of the limitations of the current treatment for these diseases. This motivated me to train in molecular oncology with the aim of carrying out translational projects with the hope of contributing to the improvement of patient's survival and quality of life.
What do you think about the development of open access publishing? What motivated you to do so?
I really appreciate open access publishing because this facilitates the access to quality investigations to all researchers around the world.
What articles and/or books have you published recently?
Uña E. "Atypical presentation of acute neurotoxicity secondary to oxaliplatin". J Oncol Pharm Pract. 2009 Dec 16. [Epub ahead of print][Pubmed]
Uña E, Trueba J, Montes JM."Unexplained liver laceration after metastasis radiofrequency ablation". World J Gastroenterol. 2009 Oct 28;15(40):5103-5.[Pubmed]
Uña E."Gastric cancer: predictors of recurrence when lymph-node dissection is inadequate". World J Surg Oncol. 2009 Sep 17;7:69.[Pubmed]
Uña E. "A Different Variable to Stratify Risk in Resected Gastric Cancer".
Ann Surg Oncol. 2009 Oct 31. [Epub ahead of print][Pubmed]
Uña E. "Sexual problems after breast cancer: the underreported symptoms".
Gynecol Oncol. 2010 Jan;116(1):147. Epub 2009 Oct 27.[Pubmed]
Uña E. "A Commentary on “Risk Factors for Renal Cell Cancer in a Japanese Population”. Clinical Medicine: Oncology 2009:3;87-90.
Uña E, Jiménez M. "Gastric Adenocarcinoma: Is Computed Tomography (CT) Useful in Preoperative Staging?". Clinical Medicine: Oncology 2009:3;91-97.
Uña E, Cuadrillero F, López-Lara F. "Drug extravasation: a dreaded complication". BMJ Case Reports 2009 [doi:10.1136/bcr.09.2008.0887]
Uña E, Tejeiro M, Alvarez M. "Primary Peritoneal Malignant Mixed Müllerian Tumor in a Young Woman: Achieving the Best Clinical Benefit". Case Rep Oncol 2009;2:162-167 (DOI: 10.1159/000235912)
Uña E. Clinical benefit and safety in gastric cancer´s treatment. Gastric Cancer Journal (Spanish edition)2009;3:20-25.
Uña E, Gandía F, Duque JL. "Tongue paralysis after orotracheal intubation in a patient with primary mediastinal tumor". Cases Journal 2009, 2:9301doi:10.1186/1757-1626-2-9301.[Pubmed]
Losa R, Fra J, López-Pousa A, Sierra M, Goitia A, Uña E, Nadal R, Del Muro JG, Gión M, Maurel J, Escudero P, Esteban E, Buesa JM. "Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas". Cancer Chemother Pharmacol. 2007 Feb;59(2):251-9.[Pubmed]
Esteban E, Fra J, Fernández Y, Corral N, Vieitez JM, Palacio I, de Sande JL, Fernández JL, Muñiz I, Villanueva N, Estrada E, Mareque B, Uña E, Buesa JM, Lacave AJ; Grupo Oncológico del Norte de España (GON). "Gemcitabine and vinorelbine (GV) versus cisplatin, gemcitabine and vinorelbine (CGV) as first-line treatment in advanced non small cell lung cancer: results of a prospective randomized phase II study". Invest New Drugs. 2006 May;24(3):241-8.[Pubmed]
The Editor in Chief of Clinical Medicine Insights: Oncology recently issued a call for papers.
Dr Uña Cidón is a member of our favorite authors program. Under the program authors are eligible to receive: prioritized peer review, prioritised author PDF, and an article processing fee discount. All former authors are eligible to join the favorite authors program.
Please describe your experience with Libertas Academica:
I would like to say that my experience with Libertas Academica has been excellent. The steps for submitting a manuscript are easy. The review process has been fast and reviewers comments have been kind and very qualified. The communication with the staff is fluent and friendly. I like the regular updates of the progress of my submitted manuscript. I appreciate these advantages.
What is the primary focus of your research?
Now and in the past my clinical research has focused primarily on gastrointestinal tumors, mainly colorectal and gastric neoplasms. I have been working on several projects related with new clinical and pathological prognostic/predictive factors, tumoral markers and its clinical utility in different clinical scenarios and biomarkers. My work has also explored the relationship between costs and effectiveness of various strategies for monitoring colon cancer.
What are the most exciting developments arising from current research in your area?
The discovery of new biomarkers in gastrointestinal tumors.
Who are your main collaborators? Please describe your work with them.
I had the good fortune of working with experts from many different fields, including pathologists, radiotherapists, surgeons, biochemical colleagues, gastroenterologists, radiologists, pharmacists... They all have been very motivated by this research. Currently the teams are multidisciplinary because this is the only way to achieve the best care for the patients and the most competent research.
How did you come to be working in your research area?
I am a young Medical Oncologist with a great interest in improving quality of care in gastrointestinal tumors. I realize that as a first step to achieve the best quality of care in current clinical practice is the motivation of all specialists involved in cancer care and close collaboration within multidisciplinary teams. But I am also aware of the limitations of the current treatment for these diseases. This motivated me to train in molecular oncology with the aim of carrying out translational projects with the hope of contributing to the improvement of patient's survival and quality of life.
What do you think about the development of open access publishing? What motivated you to do so?
I really appreciate open access publishing because this facilitates the access to quality investigations to all researchers around the world.
What articles and/or books have you published recently?
Uña E. "Atypical presentation of acute neurotoxicity secondary to oxaliplatin". J Oncol Pharm Pract. 2009 Dec 16. [Epub ahead of print][Pubmed]
Uña E, Trueba J, Montes JM."Unexplained liver laceration after metastasis radiofrequency ablation". World J Gastroenterol. 2009 Oct 28;15(40):5103-5.[Pubmed]
Uña E."Gastric cancer: predictors of recurrence when lymph-node dissection is inadequate". World J Surg Oncol. 2009 Sep 17;7:69.[Pubmed]
Uña E. "A Different Variable to Stratify Risk in Resected Gastric Cancer".
Ann Surg Oncol. 2009 Oct 31. [Epub ahead of print][Pubmed]
Uña E. "Sexual problems after breast cancer: the underreported symptoms".
Gynecol Oncol. 2010 Jan;116(1):147. Epub 2009 Oct 27.[Pubmed]
Uña E. "A Commentary on “Risk Factors for Renal Cell Cancer in a Japanese Population”. Clinical Medicine: Oncology 2009:3;87-90.
Uña E, Jiménez M. "Gastric Adenocarcinoma: Is Computed Tomography (CT) Useful in Preoperative Staging?". Clinical Medicine: Oncology 2009:3;91-97.
Uña E, Cuadrillero F, López-Lara F. "Drug extravasation: a dreaded complication". BMJ Case Reports 2009 [doi:10.1136/bcr.09.2008.0887]
Uña E, Tejeiro M, Alvarez M. "Primary Peritoneal Malignant Mixed Müllerian Tumor in a Young Woman: Achieving the Best Clinical Benefit". Case Rep Oncol 2009;2:162-167 (DOI: 10.1159/000235912)
Uña E. Clinical benefit and safety in gastric cancer´s treatment. Gastric Cancer Journal (Spanish edition)2009;3:20-25.
Uña E, Gandía F, Duque JL. "Tongue paralysis after orotracheal intubation in a patient with primary mediastinal tumor". Cases Journal 2009, 2:9301doi:10.1186/1757-1626-2-9301.[Pubmed]
Losa R, Fra J, López-Pousa A, Sierra M, Goitia A, Uña E, Nadal R, Del Muro JG, Gión M, Maurel J, Escudero P, Esteban E, Buesa JM. "Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas". Cancer Chemother Pharmacol. 2007 Feb;59(2):251-9.[Pubmed]
Esteban E, Fra J, Fernández Y, Corral N, Vieitez JM, Palacio I, de Sande JL, Fernández JL, Muñiz I, Villanueva N, Estrada E, Mareque B, Uña E, Buesa JM, Lacave AJ; Grupo Oncológico del Norte de España (GON). "Gemcitabine and vinorelbine (GV) versus cisplatin, gemcitabine and vinorelbine (CGV) as first-line treatment in advanced non small cell lung cancer: results of a prospective randomized phase II study". Invest New Drugs. 2006 May;24(3):241-8.[Pubmed]
Author interview with Dr Daniel Curcio
Dr Curcio is the author of Current Rational to Prescribe Tigecycline: Critical Analysis of the Evidence and Usage Algorithms by an Argentinean Experts Panel and Tigecycline in the Treatment of Community-Acquired Pneumonia which were recently published in Clinical Medicine Insights: Therapeutics.
The Editor in Chief of Clinical Medicine Insights: Therapeutics recently issued a call for papers.
Dr Curcio is a member of our favorite authors program. Under the program authors are eligible to receive: prioritized peer review, prioritised author PDF, and an article processing fee discount. All former authors are eligible to join the favorite authors program.
Please describe your experience with Libertas Academica:
I´m very pleased to publish my article with Libertas Academica. My article was about a very important consensus about the tigecycline use in Argentina and the rational to use this antibiotic in community-acquired pneumonia. I consider that both are very useful for all the Latin American physicians. In addition, the possibility to download the article without charge is an important issue in our region.
What is the primary focus of your research?
Antibiotic use in hospitalized patients.
What are the most exciting developments arising from current research in your area?
The development of antibiotic stewardship programs, mainly in hospitals with limited resources.
Who are your main collaborators? Please describe your work with them.
Ariel Hernán Curiale. He developed all the informatic support to collect the data and the statistical analysis of my papers.
How did you come to be working in your research area?
I am an Infectious Diseases and Clinical Bacteriology Specialist, so I am very interested in the antibiotic prescription habit in Latin American hospitals since 2000.
What do you think about the development of open access publishing? What motivated you to do so?
The open access is very important for physicians from countries with limited resources. Is a very important possibility to achieve a globalization of the knowledge
What articles and/or books have you published recently?
Curcio D., Fernández F. Tigecycline Use in Critically Ill Older Patients: Case Reports and Critical Analysis J Am Geriatrics Soc 2007;55(2):312-3.
Curcio D., Fernández F. What is the best denominator with which to measure antibiotic consumption? Clin Microbiol Infect. 2007 May;13(5):553.
Curcio D, Fernandez F, Jones RN, Ferraro MJ, Reller LB, Schreckenberger PC, Sader HS. Tigecycline disk diffusion breakpoints of Acinetobacter spp.: a clinical point of view.
J Clin Microbiol. 2007 Jun;45(6):2095.
Curcio D, Fernandez F.. Acinetobacter spp. susceptibility to tigecycline: a worldwide perspective. J Antimicrob Chemother. 2007 Aug;60(2):449-50.
Curcio D., Fernández F., Galas M., Duret F. A combination of mathematical and statistical models to distinguish between "Susceptible" and "Resistant" clusters in the susceptibility disk diffusion method. Experien publice with Acinetobacter spp. and tigecycline. J Chemother. 2007 Aug;19(4):458-61.
Curcio D., Fernández F.,Duret F. Initial Use of Tigecycline in Argentina. Rev Chilena Infectol. 2007 Dec;24(6):497-9.
Curcio D. Treatment of recurrent urosepsis with tigecycline: a pharmacological perspective J Clin Microbiol. 2008 May;46(5):1892-3.
Curcio D. Fernández F. Tigecycline for Acinetobacter baumannii Infections : Other Considerations. Clin Infect Dis. 2008 Jun 1;46(11):1797-8.
Stryjewski ME, Graham DR, Wilson SE, O'Riordan W, Young D, Lentnek A, Ross DP, Fowler VG, Hopkins A, Friedland HD, Barriere SL, Kitt MM, Corey GR; Assessment of Telavancin in Complicated Skin and Skin-Structure Infections Study.Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis. 2008 Jun 1;46(11):1683-93.
Curcio D. Tigecycline for treating bloodstream infections: a critical analysis of the available evidence. Diagn Microbiol Infect Dis. 2008 Jul;61(3):358-9;
Curcio D., Fernández F., Cané A., et al. Indications of a new antibiotic in clinical practice : results of the tigecycline initial use registry. Braz J Infect Dis 2008;12(3):198-201.
Curcio D. Fernández F . Comment on: Effect of different Mueller-Hinton agars on tigecycline disc diffusion susceptibility for Acinetobacter spp. J Antimicrob Chemother. 2008 Nov;62(5):1166-7.
Curcio D. Comment: Tigecycline treatment of Acinetobacter infections: a case series Ann Pharmacother. 2008 Nov;42(11):1717-8.
Rossi F, García P, Ronzon B, Curcio D, Dowzicky MJ. Rates of antimicrobial resistance in latin america (2004-2007) and in vitro activity of the glycylcycline tigecycline and of other antibiotics. Braz J Infect Dis. 2008 Oct;12(5):405-415.
Curcio D., Fernández F., Vergara J . et al. Late onset ventilator-associated pneumonia due to multidrug-resistant Acinetobacter spp: experience with tigecycline. J Chemother. 2009 Feb;21(1):58-62.
García P, Porte L, Curcio D. In vitro evaluation of tygecicline: Influence of Mueller-Hinton agar difusión methods and validation of E-test ® for Acinetobacter baumannii. Rev Chil Infect 2009;26(Supl 1):13-16.
Campos M, Curcio D, Seas C, et al. Tigecycline as effective as vancomycin plus aztreonam in the treatment of complicated skin and skin structure infections: Experience in Latin America. Rev Chil Infect 2009;26(Supl 1):23-31.
García P., Juliet C., Fernández A, San Martín M., Cifuentes M., Porte L., Braun S., Castillo L., Vechiola M., Tapia C., Sakurada A., Chanqueo L., Lam M., Espinoza M. y Curcio D..Estudio multicéntrico de la vigilancia de la susceptibilidad in vitro a tigeciclina en Santiago de Chile. Rev Chil Infect 2009; 26 (3): 220-226
Bantar C., Curcio D., Leal A., et al. Comparative in vitro activity of tigecycline against bacteria recovered from clinical specimens in Latin America. J Chemother. 2009 Apr;21(2):144-52.
Curcio D, Alí A, Duarte D, et al. Prescription of Antibiotics in Latin American Intensive Care Units: an Observational Study. J Chemother (in press).
Curcio D., Barcelona L., Cornistein W., et al. Current Rational to Prescribe Tigecycline: Critical Analysis of the Evidence and Usage Algorithms by an Argentinean Experts Panel. Clin Med Ther Clinical Medicine: Therapeutics 2009:1 1383-1398
Curcio D. Tigecycline in the treatment of community-acquired pneumonia. Clinical Medicine: Therapeutics 2009:1 1275-1289
Curcio D. Off-label use of antibiotics in hospitalized patients : Focus on tigecycline. J Antimicrob Chemother. 2009 Dec;64(6):1344-6.
Curcio D, Alí A, Duarte A, et al. Prescription of antibiotics in intensive care units in Latin America: an observational study. J Chemother. 2009 Nov;21(5):527-34.
Curcio D. Antibiotic stewardship: The "real world" when the resources are limited. Infect Control Hosp Epidemiol (in press)
The Editor in Chief of Clinical Medicine Insights: Therapeutics recently issued a call for papers.
Dr Curcio is a member of our favorite authors program. Under the program authors are eligible to receive: prioritized peer review, prioritised author PDF, and an article processing fee discount. All former authors are eligible to join the favorite authors program.
Please describe your experience with Libertas Academica:
I´m very pleased to publish my article with Libertas Academica. My article was about a very important consensus about the tigecycline use in Argentina and the rational to use this antibiotic in community-acquired pneumonia. I consider that both are very useful for all the Latin American physicians. In addition, the possibility to download the article without charge is an important issue in our region.
What is the primary focus of your research?
Antibiotic use in hospitalized patients.
What are the most exciting developments arising from current research in your area?
The development of antibiotic stewardship programs, mainly in hospitals with limited resources.
Who are your main collaborators? Please describe your work with them.
Ariel Hernán Curiale. He developed all the informatic support to collect the data and the statistical analysis of my papers.
How did you come to be working in your research area?
I am an Infectious Diseases and Clinical Bacteriology Specialist, so I am very interested in the antibiotic prescription habit in Latin American hospitals since 2000.
What do you think about the development of open access publishing? What motivated you to do so?
The open access is very important for physicians from countries with limited resources. Is a very important possibility to achieve a globalization of the knowledge
What articles and/or books have you published recently?
Curcio D., Fernández F. Tigecycline Use in Critically Ill Older Patients: Case Reports and Critical Analysis J Am Geriatrics Soc 2007;55(2):312-3.
Curcio D., Fernández F. What is the best denominator with which to measure antibiotic consumption? Clin Microbiol Infect. 2007 May;13(5):553.
Curcio D, Fernandez F, Jones RN, Ferraro MJ, Reller LB, Schreckenberger PC, Sader HS. Tigecycline disk diffusion breakpoints of Acinetobacter spp.: a clinical point of view.
J Clin Microbiol. 2007 Jun;45(6):2095.
Curcio D, Fernandez F.. Acinetobacter spp. susceptibility to tigecycline: a worldwide perspective. J Antimicrob Chemother. 2007 Aug;60(2):449-50.
Curcio D., Fernández F., Galas M., Duret F. A combination of mathematical and statistical models to distinguish between "Susceptible" and "Resistant" clusters in the susceptibility disk diffusion method. Experien publice with Acinetobacter spp. and tigecycline. J Chemother. 2007 Aug;19(4):458-61.
Curcio D., Fernández F.,Duret F. Initial Use of Tigecycline in Argentina. Rev Chilena Infectol. 2007 Dec;24(6):497-9.
Curcio D. Treatment of recurrent urosepsis with tigecycline: a pharmacological perspective J Clin Microbiol. 2008 May;46(5):1892-3.
Curcio D. Fernández F. Tigecycline for Acinetobacter baumannii Infections : Other Considerations. Clin Infect Dis. 2008 Jun 1;46(11):1797-8.
Stryjewski ME, Graham DR, Wilson SE, O'Riordan W, Young D, Lentnek A, Ross DP, Fowler VG, Hopkins A, Friedland HD, Barriere SL, Kitt MM, Corey GR; Assessment of Telavancin in Complicated Skin and Skin-Structure Infections Study.Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis. 2008 Jun 1;46(11):1683-93.
Curcio D. Tigecycline for treating bloodstream infections: a critical analysis of the available evidence. Diagn Microbiol Infect Dis. 2008 Jul;61(3):358-9;
Curcio D., Fernández F., Cané A., et al. Indications of a new antibiotic in clinical practice : results of the tigecycline initial use registry. Braz J Infect Dis 2008;12(3):198-201.
Curcio D. Fernández F . Comment on: Effect of different Mueller-Hinton agars on tigecycline disc diffusion susceptibility for Acinetobacter spp. J Antimicrob Chemother. 2008 Nov;62(5):1166-7.
Curcio D. Comment: Tigecycline treatment of Acinetobacter infections: a case series Ann Pharmacother. 2008 Nov;42(11):1717-8.
Rossi F, García P, Ronzon B, Curcio D, Dowzicky MJ. Rates of antimicrobial resistance in latin america (2004-2007) and in vitro activity of the glycylcycline tigecycline and of other antibiotics. Braz J Infect Dis. 2008 Oct;12(5):405-415.
Curcio D., Fernández F., Vergara J . et al. Late onset ventilator-associated pneumonia due to multidrug-resistant Acinetobacter spp: experience with tigecycline. J Chemother. 2009 Feb;21(1):58-62.
García P, Porte L, Curcio D. In vitro evaluation of tygecicline: Influence of Mueller-Hinton agar difusión methods and validation of E-test ® for Acinetobacter baumannii. Rev Chil Infect 2009;26(Supl 1):13-16.
Campos M, Curcio D, Seas C, et al. Tigecycline as effective as vancomycin plus aztreonam in the treatment of complicated skin and skin structure infections: Experience in Latin America. Rev Chil Infect 2009;26(Supl 1):23-31.
García P., Juliet C., Fernández A, San Martín M., Cifuentes M., Porte L., Braun S., Castillo L., Vechiola M., Tapia C., Sakurada A., Chanqueo L., Lam M., Espinoza M. y Curcio D..Estudio multicéntrico de la vigilancia de la susceptibilidad in vitro a tigeciclina en Santiago de Chile. Rev Chil Infect 2009; 26 (3): 220-226
Bantar C., Curcio D., Leal A., et al. Comparative in vitro activity of tigecycline against bacteria recovered from clinical specimens in Latin America. J Chemother. 2009 Apr;21(2):144-52.
Curcio D, Alí A, Duarte D, et al. Prescription of Antibiotics in Latin American Intensive Care Units: an Observational Study. J Chemother (in press).
Curcio D., Barcelona L., Cornistein W., et al. Current Rational to Prescribe Tigecycline: Critical Analysis of the Evidence and Usage Algorithms by an Argentinean Experts Panel. Clin Med Ther Clinical Medicine: Therapeutics 2009:1 1383-1398
Curcio D. Tigecycline in the treatment of community-acquired pneumonia. Clinical Medicine: Therapeutics 2009:1 1275-1289
Curcio D. Off-label use of antibiotics in hospitalized patients : Focus on tigecycline. J Antimicrob Chemother. 2009 Dec;64(6):1344-6.
Curcio D, Alí A, Duarte A, et al. Prescription of antibiotics in intensive care units in Latin America: an observational study. J Chemother. 2009 Nov;21(5):527-34.
Curcio D. Antibiotic stewardship: The "real world" when the resources are limited. Infect Control Hosp Epidemiol (in press)
Author interview with Dr Michael Wong
Dr Wong is the author of A Re-assessment of the Safety and Efficacy of Interleukin-2 for the Treatment of Renal Cell Carcinoma which was recently published in Clinical Medicine Insights: Therapeutics.
The Editor in Chief of Clinical Medicine Insights: Therapeutics recently issued a call for papers.
Dr Wongis a member of our favorite authors program. Under the program authors are eligible to receive: prioritized peer review, prioritised author PDF, and an article processing fee discount. All former authors are eligible to join the favorite authors program.
What is the primary focus of your research?
One of the major fustrations in the current treatment of cancer is that the disease often times becomes refractory to treatment. Although there are multiple reasons for this, we believe that the major issue is cancer's ability to mutate, change and adapt to therapeutic pressure. Host pathways do not possess this gene expression promiscuity, and thereby are a more "stable" therapeutic target. Our research work is directed at working out how tumors hijack host mechanisms to become malignant. The aim is to develop new therapeutic strategies directed at these pathways.
What are the most exciting developments arising from current research in your area?
Our clinical and translational research work point to 3 promising areas: tumor angiogenesis, tumor-host matrix interactions and immunomodulation of the tumor microenvironment.
In keeping with this focus, we administer high dose Interleukin-2 for advanced or metastatic kidney cancer and malignant melanoma. Our interest is in improving the long term response rate to this therapy.
Who are your main collaborators? Please describe your work with them.
Our clinical team comprises: Ms. Tammy Hecke RN, Ms. Jill Nestico NP, Mr. Anthony Jarkowski PharmD, Ms. Karen Vona NP. Our translational research team is lead by: Dr. Raya Huang PhD and Ms. Dawn Bowers BSc.
How did you come to be working in your research area?
I was motivated by the desire to make a difference in the treatment of people afflicted with advanced cancer.
What do you think about the development of open access publishing?
The ability to get the information to the people who need it or interested in it is important.
What articles and/or books have you published recently?
Wong MKK. Melanoma biology: the foundation of therapy. Community Oncol 5(3), Supp 2:6-14, 2008.
Rigual NR, Popat SR, Jayaprakash V, Jaggernauth W, Wong M. Cutaneous head and neck melanoma: the old and the new. Expert Rev Anticancer Ther 8(3):403-412 2008.
Wong, MKK. The current role of immunotherapy for renal cell carcinoma in the era of targeted therapeutics. Current Oncol Rep 10:259-263, 2008.
Chen S-C, Henry DO, Reczek PR, Wong MKK. Plasminogen activator inhibitor-1 inhibits prostate tumor growth through endothelial apoptosis. Mol Cancer Ther 7(5):1227-1236, 2008.
Chen S-C, Henry DO, Hicks DG, Reczek PR, Wong MK. Intravesical administration of plasminogen activator inhibitor type-1 inhibits in vivo bladder tumor invasion and progression. J Urol Jan;181(1):336-42, 2009.
Jarkowski III A, Wong MKK. Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature. Pharmacotherapy Apr;29(4):473-8, 2009.
The Editor in Chief of Clinical Medicine Insights: Therapeutics recently issued a call for papers.
Dr Wongis a member of our favorite authors program. Under the program authors are eligible to receive: prioritized peer review, prioritised author PDF, and an article processing fee discount. All former authors are eligible to join the favorite authors program.
What is the primary focus of your research?
One of the major fustrations in the current treatment of cancer is that the disease often times becomes refractory to treatment. Although there are multiple reasons for this, we believe that the major issue is cancer's ability to mutate, change and adapt to therapeutic pressure. Host pathways do not possess this gene expression promiscuity, and thereby are a more "stable" therapeutic target. Our research work is directed at working out how tumors hijack host mechanisms to become malignant. The aim is to develop new therapeutic strategies directed at these pathways.
What are the most exciting developments arising from current research in your area?
Our clinical and translational research work point to 3 promising areas: tumor angiogenesis, tumor-host matrix interactions and immunomodulation of the tumor microenvironment.
In keeping with this focus, we administer high dose Interleukin-2 for advanced or metastatic kidney cancer and malignant melanoma. Our interest is in improving the long term response rate to this therapy.
Who are your main collaborators? Please describe your work with them.
Our clinical team comprises: Ms. Tammy Hecke RN, Ms. Jill Nestico NP, Mr. Anthony Jarkowski PharmD, Ms. Karen Vona NP. Our translational research team is lead by: Dr. Raya Huang PhD and Ms. Dawn Bowers BSc.
How did you come to be working in your research area?
I was motivated by the desire to make a difference in the treatment of people afflicted with advanced cancer.
What do you think about the development of open access publishing?
The ability to get the information to the people who need it or interested in it is important.
What articles and/or books have you published recently?
Wong MKK. Melanoma biology: the foundation of therapy. Community Oncol 5(3), Supp 2:6-14, 2008.
Rigual NR, Popat SR, Jayaprakash V, Jaggernauth W, Wong M. Cutaneous head and neck melanoma: the old and the new. Expert Rev Anticancer Ther 8(3):403-412 2008.
Wong, MKK. The current role of immunotherapy for renal cell carcinoma in the era of targeted therapeutics. Current Oncol Rep 10:259-263, 2008.
Chen S-C, Henry DO, Reczek PR, Wong MKK. Plasminogen activator inhibitor-1 inhibits prostate tumor growth through endothelial apoptosis. Mol Cancer Ther 7(5):1227-1236, 2008.
Chen S-C, Henry DO, Hicks DG, Reczek PR, Wong MK. Intravesical administration of plasminogen activator inhibitor type-1 inhibits in vivo bladder tumor invasion and progression. J Urol Jan;181(1):336-42, 2009.
Jarkowski III A, Wong MKK. Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature. Pharmacotherapy Apr;29(4):473-8, 2009.
Tuesday, July 13, 2010
Author interview with Dr Thomas Ostermann
Dr Ostermann is the author of Linguistic processing and classification of semi structured bibliographic data on complementary medicine which was recently published in Cancer Informatics.
The Editor in Chief of Cancer Informatics recently issued a call for papers.
Dr Ostermann is a member of our favorite authors program. Under the program authors are eligible to receive: prioritized peer review, prioritised author PDF, and an article processing fee discount. All former authors are eligible to join the favorite authors program.
What is the primary focus of your research?
I am working at the Center of Integrative Medicine at Witten/Herdecke University with two main topics:
- The development and application of methods for Health Services Research
- The use of modern web-technology for the creation of databases like CAMbase
Both topics serve to strenghten the Evidence-base of Complementary and Alternative Medicine (CAM)
What are the most exciting developments arising from current research in your area?
It is fascinating to see how things develop in the field of web technology. Almost 10 years ago we started our CAMbase project, a database on CAM and were faced with problems like server response times, speed of internet access and so on, which nowadays do not play that role anymore. Additionally new semantic web standards like XML have been developed and is quite amazing to see the new possibilities alongside this innovations. This has influenced our work dramatically and were are now capable to develop database features like "tag clouds" which were impossible 10 years ago.
Who are your main collaborators? Please describe your work with them.
There is of course my team Christa Raak and Hartmut Zillmann with with whom I have been working for the past years. Our main collaborators are the Institutes for Art Therapy Research at the Universities in Nuertingen and Ottersberg (both in Germany). They had the idea of developing a bibliographical database on Art Therapy. As a mathematician working in medicine I am trying to identify the needs of our partners and "translate" them into technical terms (i.e. database structures) which then are realized by Hartmut. Normally this process quickly converges towards a fixed state...
Another important and much younger collaboration is given with the ICCR-project. ICCR is an international collaboration of national and/or government-funded online complementary and alternative medicine (CAM) information providers which tries to map the landscape of Internet resources on CAM, develop guidelines on aspects of CAM information provision and bring togehter the main actors of this field. CAMbase was one of the centers that initiated the start-up of the ICCR in 2007 and we are meeting on a regular basis to discuss new information trends particularly with respect to patient information.
How did you come to be working in your research area?
After finishing my Ph-D on speech recognition in 1998 at my university I was looking for a academic position within the limits of mathematics and medicine. At that time the German government-funded project "Unconventional Medical Approaches (German acronym: UMR) was searching for a methodologist for health services research in CAM and I was quite impressed about the possibilities and ideas within that field. One of the tasks was to bring a database of self-collected bibliographical metadata online. That was the start of CAMbase and after a prototype was finished we made an application the the German Research Council (DFG) which was voted positive. From that point new projects (and also new funders like the Software AG Foundation) came in and this is how it all began.
What do you think about the development of open access publishing? What motivated you to do so?
When we developed CAMbase one of our internal rules was that bibliographical information should be free and accessable for everyone without registration fees. I remember that not all of our contacts at that time agreed on that but that was our idea behind CAMbase. At that time (I suppose it was in 2000) the first Open access publishers started and we thought that this is in congruence with our ideas. From a personal point of view I like the idea that full-texts of my research are available through MEDLINE with only one or two mouse-clicks.
What articles and/or books have you published recently?
Recently I have published several articles with my colleague Elke Jeschke about prescribing patterns in a network of CAM-physicians, i.e.
Jeschke E, Ostermann T, Vollmar HC, Kroz M, Bockelbrink A, Witt CM, Willich SN, Matthes H. Evaluation of prescribing patterns in a German network of CAM physicians for the treatment of patients with hypertension: a prospective observational study. BMC Fam Pract.; 10(1):78.
Another quite recent article deals with "Knowledge transfer for the management of dementia: a cluster randomised trial of blended learning in general practice" where I am a co-author.
The last article I would like to mention is a methjodological paper on "Regression toward the mean--a detection method for unknown population mean based on Mee and Chua's algorithm." published with my colleague Rainer Lüdtke in BMC Med Res Methodol. 2008;8:52.
Additional Information
Faculty Website
http://medizin.uni-wh.de/humanmedizin/lehrstuehle/uebersicht/lehrstuhl-fuer-medizintheorie-integrative-und-anthroposophische-medizin/personen/thomas-ostermann/?L=0
The Editor in Chief of Cancer Informatics recently issued a call for papers.
Dr Ostermann is a member of our favorite authors program. Under the program authors are eligible to receive: prioritized peer review, prioritised author PDF, and an article processing fee discount. All former authors are eligible to join the favorite authors program.
What is the primary focus of your research?
I am working at the Center of Integrative Medicine at Witten/Herdecke University with two main topics:
- The development and application of methods for Health Services Research
- The use of modern web-technology for the creation of databases like CAMbase
Both topics serve to strenghten the Evidence-base of Complementary and Alternative Medicine (CAM)
What are the most exciting developments arising from current research in your area?
It is fascinating to see how things develop in the field of web technology. Almost 10 years ago we started our CAMbase project, a database on CAM and were faced with problems like server response times, speed of internet access and so on, which nowadays do not play that role anymore. Additionally new semantic web standards like XML have been developed and is quite amazing to see the new possibilities alongside this innovations. This has influenced our work dramatically and were are now capable to develop database features like "tag clouds" which were impossible 10 years ago.
Who are your main collaborators? Please describe your work with them.
There is of course my team Christa Raak and Hartmut Zillmann with with whom I have been working for the past years. Our main collaborators are the Institutes for Art Therapy Research at the Universities in Nuertingen and Ottersberg (both in Germany). They had the idea of developing a bibliographical database on Art Therapy. As a mathematician working in medicine I am trying to identify the needs of our partners and "translate" them into technical terms (i.e. database structures) which then are realized by Hartmut. Normally this process quickly converges towards a fixed state...
Another important and much younger collaboration is given with the ICCR-project. ICCR is an international collaboration of national and/or government-funded online complementary and alternative medicine (CAM) information providers which tries to map the landscape of Internet resources on CAM, develop guidelines on aspects of CAM information provision and bring togehter the main actors of this field. CAMbase was one of the centers that initiated the start-up of the ICCR in 2007 and we are meeting on a regular basis to discuss new information trends particularly with respect to patient information.
How did you come to be working in your research area?
After finishing my Ph-D on speech recognition in 1998 at my university I was looking for a academic position within the limits of mathematics and medicine. At that time the German government-funded project "Unconventional Medical Approaches (German acronym: UMR) was searching for a methodologist for health services research in CAM and I was quite impressed about the possibilities and ideas within that field. One of the tasks was to bring a database of self-collected bibliographical metadata online. That was the start of CAMbase and after a prototype was finished we made an application the the German Research Council (DFG) which was voted positive. From that point new projects (and also new funders like the Software AG Foundation) came in and this is how it all began.
What do you think about the development of open access publishing? What motivated you to do so?
When we developed CAMbase one of our internal rules was that bibliographical information should be free and accessable for everyone without registration fees. I remember that not all of our contacts at that time agreed on that but that was our idea behind CAMbase. At that time (I suppose it was in 2000) the first Open access publishers started and we thought that this is in congruence with our ideas. From a personal point of view I like the idea that full-texts of my research are available through MEDLINE with only one or two mouse-clicks.
What articles and/or books have you published recently?
Recently I have published several articles with my colleague Elke Jeschke about prescribing patterns in a network of CAM-physicians, i.e.
Jeschke E, Ostermann T, Vollmar HC, Kroz M, Bockelbrink A, Witt CM, Willich SN, Matthes H. Evaluation of prescribing patterns in a German network of CAM physicians for the treatment of patients with hypertension: a prospective observational study. BMC Fam Pract.; 10(1):78.
Another quite recent article deals with "Knowledge transfer for the management of dementia: a cluster randomised trial of blended learning in general practice" where I am a co-author.
The last article I would like to mention is a methjodological paper on "Regression toward the mean--a detection method for unknown population mean based on Mee and Chua's algorithm." published with my colleague Rainer Lüdtke in BMC Med Res Methodol. 2008;8:52.
Additional Information
Faculty Website
http://medizin.uni-wh.de/humanmedizin/lehrstuehle/uebersicht/lehrstuhl-fuer-medizintheorie-integrative-und-anthroposophische-medizin/personen/thomas-ostermann/?L=0
Author interview with Dr Nicolas Carels
Dr Carels is the author of Classifying coding DNA with nucleotide statistics and Universal Features for the Classification of Coding and Non-coding DNA Sequences which were recently published in Bioinformatics and Biology Insights.
The Editor in Chief of Bioinformatics and Biology Insights recently issued a call for papers.
Dr Carels is a member of our favorite authors program. Under the program authors are eligible to receive: prioritized peer review, prioritised author PDF, and an article processing fee discount. All former authors are eligible to join the favorite authors program.
Please describe your experience with Libertas Academica:
In my experience, Libertas Academica combines professional publication standards with efficiency and speed in manuscript managment. The staff dedicates exceptional attention to authors’ concerns. Manuscripts are processed straightforward, which is in line with what we should expect from science sharing.
What is the primary focus of your research?
The primary focus of my research is the integration of the various aspects of genomics with biological applications such as new drug development.
What are the most exciting developments arising from current research in your area?
I guess that the most exciting development at the moment is the ongoing science integration. This integration is placing scientific areas such as biology, mathematics, electronics, material sciences etc. together while these were traditionally apart. A very exciting new frontier to overcome is for sure the alliance between electronics and biology, in particular the development of interfaces between electronics and nervous system.
Who are your main collaborators? Please describe your work with them.
I am working at FIOCRUZ a public institution for human health whose primary focus is parasitology. I am working within the philosophical framework of Dr. Carlos Morel and his collaborators, I aim to contribute to what is called: the Chemogenomics.
How did you come to be working in your research area?
I started as an agronomist and went successively through phytopathology, plant genetic mapping, genome organization and transcriptome investigations. Now I am starting to look at relationships between genomes and their environment taking pharmaceutical concerns into consideration.
What do you think about the development of open access publishing? What motivated you to do so?
Science production is the exercice of (i) making associations between ideas and facts, (ii) experiencing intuitions and (iii) describing reproducible and significant differences. Science products are valuable. For these reasons, I believe that science must be open access. In my opinion, the best science is free. Science is a humanity investment. The excercice of making science is a complex issue that depends on broad indirect participation. The price is high and the return must be given to everybody. This is the best way to make it sustainable and largely accepted.
What articles and/or books have you published recently?
In 2009, I published:
Carels, N. and Frias, D. (2009) Classifying coding DNA with nucleotide statistics. Bioinformatics and Biology Insights 3, 141-154.
Carels, N., Vidal, R. and Frias, D. (2009) Universal Features for the Classification of Coding and Non-coding DNA Sequences. Bioinformatics and Biology Insights 3, 37-49.
Carels, N. (2009) Jatropha curcas: A Review. In: Kader, J.C. and Delseny, M. (Eds.). Advances in Botanical Research 50, 39-86.
Lima, L.S., Gramacho, K.P., Carels, N., Novais, R., Gaiotto, F.A., Lopes, U.V., Gesteira, A.S., Zaidan, H.A., Cascardo, J.C.M., Pires, J.L. and Micheli, F. (2009) Single nucleotide polymorphisms from Theobroma cacao expressed sequence tags associated with witches broom disease in cacao. Genetics and Molecular Research 8, 799-808.
Additional Information
Faculty Website
The Editor in Chief of Bioinformatics and Biology Insights recently issued a call for papers.
Dr Carels is a member of our favorite authors program. Under the program authors are eligible to receive: prioritized peer review, prioritised author PDF, and an article processing fee discount. All former authors are eligible to join the favorite authors program.
Please describe your experience with Libertas Academica:
In my experience, Libertas Academica combines professional publication standards with efficiency and speed in manuscript managment. The staff dedicates exceptional attention to authors’ concerns. Manuscripts are processed straightforward, which is in line with what we should expect from science sharing.
What is the primary focus of your research?
The primary focus of my research is the integration of the various aspects of genomics with biological applications such as new drug development.
What are the most exciting developments arising from current research in your area?
I guess that the most exciting development at the moment is the ongoing science integration. This integration is placing scientific areas such as biology, mathematics, electronics, material sciences etc. together while these were traditionally apart. A very exciting new frontier to overcome is for sure the alliance between electronics and biology, in particular the development of interfaces between electronics and nervous system.
Who are your main collaborators? Please describe your work with them.
I am working at FIOCRUZ a public institution for human health whose primary focus is parasitology. I am working within the philosophical framework of Dr. Carlos Morel and his collaborators, I aim to contribute to what is called: the Chemogenomics.
How did you come to be working in your research area?
I started as an agronomist and went successively through phytopathology, plant genetic mapping, genome organization and transcriptome investigations. Now I am starting to look at relationships between genomes and their environment taking pharmaceutical concerns into consideration.
What do you think about the development of open access publishing? What motivated you to do so?
Science production is the exercice of (i) making associations between ideas and facts, (ii) experiencing intuitions and (iii) describing reproducible and significant differences. Science products are valuable. For these reasons, I believe that science must be open access. In my opinion, the best science is free. Science is a humanity investment. The excercice of making science is a complex issue that depends on broad indirect participation. The price is high and the return must be given to everybody. This is the best way to make it sustainable and largely accepted.
What articles and/or books have you published recently?
In 2009, I published:
Carels, N. and Frias, D. (2009) Classifying coding DNA with nucleotide statistics. Bioinformatics and Biology Insights 3, 141-154.
Carels, N., Vidal, R. and Frias, D. (2009) Universal Features for the Classification of Coding and Non-coding DNA Sequences. Bioinformatics and Biology Insights 3, 37-49.
Carels, N. (2009) Jatropha curcas: A Review. In: Kader, J.C. and Delseny, M. (Eds.). Advances in Botanical Research 50, 39-86.
Lima, L.S., Gramacho, K.P., Carels, N., Novais, R., Gaiotto, F.A., Lopes, U.V., Gesteira, A.S., Zaidan, H.A., Cascardo, J.C.M., Pires, J.L. and Micheli, F. (2009) Single nucleotide polymorphisms from Theobroma cacao expressed sequence tags associated with witches broom disease in cacao. Genetics and Molecular Research 8, 799-808.
Additional Information
Faculty Website
http://www.dbbm.fiocruz.br/labwim/bioinfoteam/index.pl?action=gencomp
Subscribe to:
Posts (Atom)
Posts
